Pharma companies set for strong performance in March 2025 quarter amid earning (...)
Sun Pharma is expected to post a 9% year-on-year revenue growth, supported by its US specialty portfolio and steady growth in chronic therapies in India.
Site référencé: The Economic Times
The Economic Times
Right time to take profit off the table in pharma ; defence a structural buy : Rajiv Batra
22/08/2025
Private Chinese firm producing oil in Venezuela under rare 20-year pact, source says
22/08/2025
Fed officials divided ahead of Powell’s Jackson Hole Speech
22/08/2025
Apollo Micro Systems shares surge 15% following Rs 25 cr order wins from DRDO, other defence PSUs
22/08/2025
Nazara Tech shares tumble 18% in 3 sessions on gaming bill jitters ; what should investors do now ?
22/08/2025
Warburg-backed Avanse is said to mull IPO delay on US visa rules
22/08/2025
